Castle Biosciences Quarterly Income Statement
NASDAQ: CSTLHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Castle Biosciences revenue and earnings
In the quarter ended Jun 30, 2026, Castle Biosciences generated $103.5 million in revenue, up 20.1% from the same quarter a year earlier. Castle Biosciences reported a net loss of $2.1 million, compared with net income of $4.5 million a year earlier. Gross margin was 77.1% (down from 79.5%) and operating margin -3.0%.
Diluted earnings per share came in at -$0.07, down from $0.15.
Summary generated from market data by MetaCap's automated system. Methodology
Castle Biosciences income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 103.55M | 83.68M | 87.01M | 83.04M | 86.19M | 87.99M | 86.31M | 85.78M | 87.00M | 72.97M | 66.12M | 61.49M |
| Revenue growth (YoY) | +20.14% | -4.90% | +0.81% | -3.19% | -0.94% | +20.57% | +30.54% | +39.50% | +73.53% | +73.59% | +72.47% | +66.15% |
| Cost of Revenue | 23.70M | 20.53M | 18.32M | 18.70M | 17.63M | 16.38M | 16.18M | 15.61M | 14.52M | 13.89M | 12.42M | 11.32M |
| Gross Profit | 79.85M | 63.15M | 68.69M | 64.34M | 68.56M | 71.61M | 70.13M | 70.17M | 72.48M | 59.08M | 53.70M | 50.17M |
| Operating Expenses | 82.92M | 81.55M | 72.52M | 71.14M | 72.81M | 99.53M | 66.08M | 65.09M | 67.47M | 64.55M | 59.35M | 59.81M |
| Research & Development | 14.54M | 14.43M | 13.52M | 12.96M | 12.79M | 12.59M | 11.77M | 12.32M | 14.14M | 13.81M | 12.99M | 12.92M |
| Selling, General & Admin | 66.12M | 64.90M | 56.73M | 55.91M | 58.06M | 58.62M | 49.97M | 50.50M | 51.09M | 48.49M | 44.09M | 44.62M |
| Operating Income | -3.07M | -18.41M | -3.83M | -6.80M | -4.25M | -27.93M | 4.05M | 5.08M | 5.01M | -5.47M | -5.66M | -9.64M |
| Interest Expense | 193.00K | 134.00K | 24.00K | 24.00K | 9.00K | 8.00K | 92.00K | 192.00K | 216.00K | 12.00K | 2.00K | 2.00K |
| Other Income (Expense) | -153.00K | -439.00K | 96.00K | 48.00K | 0 | 0 | 0 | 0 | — | — | — | — |
| Income Tax | 370.00K | 109.00K | -382.00K | 115.00K | -4.67M | -423.00K | -1.71M | 6.01M | -1.03M | 45.00K | 39.00K | 32.00K |
| Net Income | -2.06M | -14.52M | -2.33M | -501.00K | 4.52M | -25.85M | 9.59M | 2.27M | 8.92M | -2.53M | -2.58M | -6.91M |
| Net Income growth (YoY) | -145.54% | — | -124.32% | -122.08% | -49.29% | — | — | — | — | — | — | — |
| EPS (Basic) | -0.07 | -0.49 | -0.07 | -0.02 | 0.16 | -0.90 | 0.35 | 0.08 | 0.32 | -0.09 | -0.08 | -0.26 |
| EPS (Diluted) | -0.07 | -0.49 | -0.06 | -0.02 | 0.15 | -0.90 | 0.32 | 0.08 | 0.31 | -0.09 | -0.08 | -0.26 |
| Shares Outstanding (Basic) | 30.40M | 29.89M | — | 29.07M | 28.91M | 28.61M | — | 27.84M | 27.65M | 27.48M | — | 26.83M |
| Shares Outstanding (Diluted) | 30.40M | 29.89M | — | 29.07M | 29.55M | 28.61M | — | 29.40M | 28.74M | 27.48M | — | 26.83M |
| EBITDA | 1.00M | -14.48M | -50.00K | -2.99M | -837.00K | 1.84M | 9.82M | 8.62M | 8.36M | -2.13M | -2.43M | -6.47M |
| Gross Margin | 77.11% | 75.46% | 78.95% | 77.48% | 79.55% | 81.38% | 81.25% | 81.80% | 83.31% | 80.96% | 81.21% | 81.59% |
| Operating Margin | -2.96% | -22.00% | -4.40% | -8.19% | -4.93% | -31.74% | 4.69% | 5.92% | 5.76% | -7.50% | -8.56% | -15.68% |
| Net Margin | -1.99% | -17.35% | -2.68% | -60.00% | 5.25% | -29.38% | 11.11% | 2.65% | 10.25% | -3.47% | -3.90% | -11.23% |
This table shows 12 quarterly periods of Castle Biosciences's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow CSTL's reporting calendar. What is a income statement?